Ranbaxy Exits Pfizer's Suit Over Generic Rapamune
By Lana Birbrair ( February 6, 2012, 7:32 PM EST) -- Ranbaxy Laboratories Ltd. on Monday exited a patent infringement suit launched by Pfizer Inc. against it and Watson Pharmaceuticals Inc. in Delaware federal court in response to abbreviated new drug applications to introduce a generic version of the organ rejection drug Rapamune....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.